Andrew Saik - Nov 8, 2023 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC. (ICPT)

Signature
/s/ Rocco Venezia, as attorney-in-fact
Stock symbol
ICPT
Transactions as of
Nov 8, 2023
Transactions value $
-$1,297,035
Form type
4
Date filed
11/13/2023, 02:40 PM
Previous filing
Sep 25, 2023
Next filing
Jun 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICPT Common Stock Disposition pursuant to a tender of shares in a change of control transaction -$437K -23K -100% $19.00 0 Nov 8, 2023 Direct F1
transaction ICPT Common Stock Disposed to Issuer -$860K -45.2K -100% $19.00 0 Nov 8, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ICPT Option to Purchase Common Stock Disposed to Issuer -17.6K -100% 0 Nov 8, 2023 Common Stock 17.6K $14.44 Direct F4
transaction ICPT Option to Purchase Common Stock Disposed to Issuer -24K -100% 0 Nov 8, 2023 Common Stock 24K $18.40 Direct F4
transaction ICPT Option to Purchase Common Stock Disposed to Issuer -72.5K -100% 0 Nov 8, 2023 Common Stock 72.5K $20.84 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Andrew Saik is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2 Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3 Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4 Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5 Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.